SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, has announced the initiation of a critical phase in the preclinical development of its lead drug candidate GEP-44, a multi-receptor peptide designed to treat obesity and type 2 diabetes. The company is launching a Good Laboratory Practice (GLP) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (FDA) requirements, a necessary step before filing an Investigational New Drug (IND) application and proceeding to first-in-human clinical trials.
This development positions SureNano as an agile entrant in the rapidly expanding GLP-1 market, which has seen significant growth due to the success of drugs like Ozempic and Wegovy. GEP-44 is a patented second-generation incretin-based therapy that the company believes offers improved tolerability and potential non-injectable delivery options. SureNano secured licensing rights to the compound from Syracuse University.
Dr. Nihar Pandey, Chief Scientific Officer at SureNano, emphasized the importance of this milestone. "Initiating these U.S. Food and Drug Administration IND-enabling studies is a major milestone for SureNano Science and GlucaPharm, moving us firmly towards the final, rigorous evaluation in various clinical phases before entering the clinic," said Dr. Pandey. "Partnering with a globally renowned CRO like LabCorp will ensure our studies meet the highest regulatory standards. This package is vital to de-risk our lead candidate and is designed to support our strategy of launching a Phase I clinical trial in Australia."
The company's focus on obesity and metabolic disorders addresses a large and growing global health market. According to the World Health Organization, obesity has nearly tripled worldwide since 1975, driving demand for effective treatments. SureNano's approach targets multiple receptors to potentially enhance efficacy and minimize side effects compared to existing single-receptor therapies.
SureNano Science acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company, to advance GEP-44. The company also has an initial business in the sale and distribution of the SureNano surfactant, a food-grade compound used for creating nanoemulsions. However, the company is now pivoting toward becoming a pharmaceutical-focused entity through the advancement of GEP-44.
The initiation of these preclinical studies is a significant step forward for SureNano, as it moves from early-stage research to clinical development. If successful, GEP-44 could offer a new treatment option for millions of patients with obesity and type 2 diabetes, potentially differentiating itself through improved tolerability and alternative delivery methods.
For the full article, visit https://ibn.fm/78hI3. For more information about SureNano Science, visit their newsroom at https://ibn.fm/SURNF.
